Wangsu Science & Technology invests up to 7.5 bn yuan in wealth products

Wangsu Science & Technology Co., Ltd. and its subsidiaries have utilized proprietary funds to purchase a variety of wealth management products, as approved by the board of directors and shareholders. The company committed an aggregate amount not exceeding 7.5 billion yuan (or equivalent in foreign currency) for these investments. These include large-denomination certificates of deposit, structured deposits, income certificates, and other low-to-medium risk products from banks, securities firms, fund management companies, insurance companies, and trust companies. The investment mandate is valid for 12 months from the shareholder approval date, with funds rolled over as needed, and an investment term extending to April 13, 2026.

As of July 1, 2025, the company has initiated multiple investments. Notable recent transactions include 20,000,000 yuan in a low-risk product with ICBC Wealth Management and 14,193,600 yuan in a medium-to-low risk product with CICC Asset Management, both yielding floating returns. Additional investments span various financial institutions like Guojun Asset Management, Everbright Wealth Management, and Huatai Financial Holdings, with product types ranging from medium-to-low risk to low risk, and yields varying from fixed rates such as 1.00%-1.80% to floating returns. Wangsu Science & Technology aims to maximize value for shareholders while maintaining sufficient liquidity for its core operations.

The company has established robust internal controls, including "Foreign Investment Management System" and "Entrusted Wealth Management System," to oversee approval, information disclosure, and risk management of these investments. These measures are designed to ensure that investments align with the company's "regulated operations, risk prevention, prudent investment, and capital preservation and appreciation" principles. The company also states that these investments will not impact its normal business operations.